Skip to main content
Injectables

Profhilo vs SKINVIVE: Which Skin Booster Is Better, and Can You Get Profhilo in the US?

Profhilo vs SKINVIVE head-to-head: what is in each syringe, how many sessions you need, what the trials found, side effect rates, US availability in 2026 and who suits which.

A
Anti Aging Care Editorial Team
13 min read

Profhilo and SKINVIVE are the two skin boosters people compare most often. Both are hyaluronic acid (HA) injections meant to improve skin quality (hydration, smoothness, crepiness and fine lines) rather than add volume like a filler. The short answer: SKINVIVE is the only one of the two you can legally get in the United States. The FDA approved it for cheek smoothness in May 2023 and for neck lines in June 2026, and it has randomized, controlled trial data behind both uses. Profhilo is not FDA-approved. It is widely used in Europe, the UK, Asia and Australia, and its US rights were licensed to Evolus in July 2026, but Evolus itself projects US commercialization in 2030. If you live outside the US and can choose either, the decision comes down to the product's design: Profhilo is a very concentrated, non-crosslinked HA that is spread under the skin from 5 points per side over two sessions, while SKINVIVE is a lightly crosslinked HA gel with lidocaine injected as many tiny droplets in one session.

The short answer

  • US readers: SKINVIVE is your FDA-approved option. Any "Profhilo" offered in a US clinic today is an unapproved product, and the FDA says the risks of unapproved products "are not known."
  • What they are: Profhilo contains 64 mg of HA in 2 mL (32 mg high-weight plus 32 mg low-weight HA, no chemical crosslinker). SKINVIVE contains 12 mg/mL of BDDE-crosslinked HA with 0.3% lidocaine.
  • Sessions: Profhilo is usually given as 2 sessions about 4 weeks apart. SKINVIVE is a single session with an optional touch-up about a month later.
  • Evidence: SKINVIVE has larger, controlled US trials (202 participants for cheeks, 159 for neck lines). Profhilo's evidence is mostly small open-label studies plus very large post-marketing safety data (more than 1 million patients).
  • Results: Both are subtle. In SKINVIVE's cheek trial, 57.9% of treated people improved by at least one grade at 1 month vs 4.5% of untreated controls. In Profhilo's 64-woman Italian study, improvements were still significant 3 months after the second session.
  • Neither replaces filler, Botox or a facelift. They don't lift sagging jowls or restore lost cheek volume.

Profhilo vs SKINVIVE at a glance

Profhilo SKINVIVE (Juvéderm Volite)
Maker IBSA (Switzerland/Italy) Allergan Aesthetics (AbbVie)
US status, Nov 2026 Not FDA-approved FDA-approved: cheeks (2023), neck lines (2026)
HA type 64 mg/2 mL hybrid complexes, not crosslinked 12 mg/mL crosslinked HA
Lidocaine No Yes, 0.3%
Usual course 2 sessions, 4 weeks apart 1 session plus optional touch-up
Injection pattern 5 points per side (BAP) Many tiny microdroplets
How long it lasts Key study followed patients to 16 weeks Cheek and neck benefit shown at 6 months
Best trial evidence Small open-label studies Randomized, evaluator-blind controlled trials

What is actually in each syringe?

Profhilo: a lot of loose hyaluronic acid

Profhilo is made with IBSA's patented NAHYCO thermal process, which bonds high- and low-molecular-weight HA into "hybrid cooperative complexes" without a chemical crosslinker. Each 2 mL syringe holds 32 mg of high-molecular-weight HA (1,100 to 1,400 kDa) and 32 mg of low-molecular-weight HA (80 to 100 kDa), a 3.2% HA concentration. Because it is very fluid, it spreads through the tissue after injection rather than sitting where it is placed. The theory, supported mainly by lab work, is that the low-weight fraction signals fibroblasts to make more collagen and elastin, which is why IBSA calls it "bio-remodeling" rather than filling.

SKINVIVE: a lighter, crosslinked gel

SKINVIVE (sold as Juvéderm Volite outside the US, per the FDA's approval summary) is a 12 mg/mL HA gel crosslinked with BDDE, the same crosslinker used in Juvéderm fillers, with 0.3% lidocaine for comfort. Crosslinking slows breakdown, which is the main reason a single session can hold up for around six months. Its approved use is intradermal injection for cheek smoothness and intradermal and/or subdermal injection for horizontal neck lines in adults over 21.

Is Profhilo FDA-approved in 2026?

No. As of November 2026, Profhilo has no FDA approval. Here is the timeline:

  • July 7, 2026: IBSA granted Evolus an exclusive license to develop and sell Profhilo in the US. Evolus's SEC filing says it is responsible for "development, clinical and regulatory activities intended to support" FDA approval, so the US clinical work is still ahead.
  • August 5, 2026: In its second-quarter results, Evolus listed "anticipated U.S. commercialization in 2030." That is a company forecast, not an FDA decision.

Injectable HA products are regulated as medical devices, and the FDA tells patients not to buy dermal filler products online "because they could be counterfeit products or products that are not approved for use in the U.S." If you are in the US and a provider offers Profhilo, ask where the product came from, and consider an FDA-approved alternative instead.

What did the SKINVIVE trials find?

Cheek smoothness (FDA approval, 2023)

In a randomized, evaluator-blind trial, 131 people received SKINVIVE (VYC-12L) and 71 were untreated controls. Participants were 86.1% female, with a median age of 58. At 1 month:

  • 57.9% of treated people improved by at least one grade on the cheek smoothness scale, vs 4.5% of controls.
  • 58.3% improved on the fine lines scale, vs 5.4% of controls.
  • Responder rates held through 6 months (55.6% for smoothness and 63.2% for fine lines).

An earlier single-arm study of 131 people treated with the European version (VYC-12) found a 96.2% responder rate for cheek roughness at month 1, falling to 76.3% at month 4 and 34.9% at month 6, with hydration still improved at month 9. That fade is a useful reminder that "lasts six months" means some benefit at six months, not full results.

Neck lines (FDA approval, June 2026)

In the neck trial, 105 people were treated and 54 were randomized to a no-treatment control. According to the FDA-approved directions for use:

  • At 1 month, 74.8% of treated participants improved by at least one grade on the transverse neck lines scale, vs 16.1% of controls.
  • At 6 months, 66.0% (64 of 97) still showed at least a one-grade improvement.
  • After a repeat treatment, responder rates reached 88.1% at 1 month.

What does the Profhilo research show?

Profhilo's evidence base is broad in body areas but thin on controlled trials:

  • The core face study (2016): 64 women aged 38 to 60 at one Italian site received injections at 5 points per side, twice, 4 weeks apart. Clinical scales, self-assessment and most instrument measurements improved by week 4 or 8 and were still significant at week 16, three months after the second session. There was no control group.
  • Neck (2022): 25 people aged 40 to 65 had two sessions 30 days apart, with improvement in neck roughness and laxity at 1 and 4 months.
  • Asian skin (2025): in 30 Chinese women, skin hydration and transepidermal water loss improved significantly by week 12, while some wrinkle and elasticity changes were not significant in pairwise comparisons.
  • A placebo-controlled test (2026): a small triple-blind split-face trial (12 women) injected Profhilo on one side of the mouth area and saline on the other. Profhilo improved wrinkles and pore size, but dermal thickness rose on both sides, so that effect "did not exceed the placebo effect," and 54.5% of participants were dissatisfied with results.
  • Systematic review: a review of 9 studies (278 participants) reported improvements in laxity, hydration, elasticity and density, but most included studies were small and uncontrolled.
  • Versus another booster: in a 24-woman split-face study, Profhilo and Belotero Revive both improved hydration and elasticity, with no significant difference between them.

No published head-to-head trial has compared Profhilo directly with SKINVIVE/Volite.

How do side effects compare?

Both have similar common reactions because both involve multiple needle passes with HA: redness, swelling, small bumps, bruising and tenderness that usually settle within days.

Reaction Profhilo SKINVIVE (cheek trial)
Any injection-site reaction 23% in the 2016 face study 79.4% recorded in patient diaries
Most common Swelling, redness, discomfort Redness 68.8%, bumps 63.3%, swelling 61.3%
Treatment-related adverse events 0.034% in post-marketing reports 3.0% of participants (mostly mild)

These numbers are not directly comparable. SKINVIVE's figures come from a trial where participants logged every reaction in a daily diary for 30 days, which captures far more minor redness and bumps. Profhilo's 0.034% comes from about 1.09 million patients treated from 2018 to 2023, but post-marketing reports rely on voluntary reporting and undercount side effects. In SKINVIVE's cheek trial, most diary reactions were mild and lasted 7 days or less.

The rare but serious risk for any HA injection is accidental injection into a blood vessel, which can cause skin necrosis or vision loss. The FDA lists this as the most concerning dermal filler risk. One advantage of HA products is that they can be dissolved with hyaluronidase in an emergency (see our guide to filler dissolving with hyaluronidase and vascular occlusion).

Which skin booster suits which concern?

Your main concern Better fit Why
Rough, dull cheek texture SKINVIVE Approved and trialed for cheek smoothness
Horizontal neck lines SKINVIVE Approved for neck lines; 74.8% responders
Crepey, lax skin over a wide area (outside the US) Profhilo Fluid HA spreads across the face, neck, décolletage
Low pain tolerance SKINVIVE Contains lidocaine
Fewest appointments SKINVIVE One session, optional touch-up
Sagging jowls or volume loss Neither Needs filler, biostimulators or surgery

If your skin looks tired but your structure is fine, either type of booster can help modestly. If the real problem is volume loss or sagging, a booster alone usually disappoints; see biostimulator fillers and Sculptra. For collagen-focused alternatives, compare polynucleotide treatments.

How much do they cost?

Neither product has a published national average price. The American Society of Plastic Surgeons lists an average physician fee of $715 for hyaluronic acid fillers in its latest statistics. That figure is for HA filler treatments generally, not SKINVIVE specifically, and excludes facility fees and regional differences. SKINVIVE is priced by syringe, so your total depends on how much is used: the studied maximum was 6.0 mL for the cheeks and 5.0 mL for the neck (initial plus touch-up). Profhilo's two-session course is usually priced as a package outside the US. Ask for the exact number of syringes and whether a touch-up is included before you book.

What happens at the appointment?

Profhilo: after cleansing, the injector places small deposits at five standard points on each side of the face, known as the BAP (Bio Aesthetic Points) technique. You may see small bumps for several hours as the product spreads. The second session follows about four weeks later.

SKINVIVE: the injector places many tiny droplets across the treatment area with a fine needle (or a needle plus cannula in the neck study). The lidocaine numbs as it goes. A touch-up can be done after about 30 days if needed.

For both, avoid makeup, heavy exercise and very hot environments for the rest of the day, and expect redness and small bumps to fade over a few days.

Frequently asked questions

Is Profhilo better than SKINVIVE?

There is no head-to-head trial, so no one can say one is better overall. SKINVIVE has stronger controlled-trial evidence and is FDA-approved; Profhilo has a longer real-world track record outside the US and suits people who want a spreading treatment for crepey skin across larger areas.

Can I get Profhilo in the US?

Not legally as an approved product. Profhilo had no FDA approval as of November 2026. Evolus licensed US rights in July 2026 and forecasts US commercialization in 2030.

Is SKINVIVE the same as Volite?

Yes. The FDA's approval summary states that SKINVIVE is the product marketed as Juvéderm Volite outside the US.

How long do Profhilo and SKINVIVE last?

SKINVIVE's cheek and neck benefits were measured out to 6 months, and the neck trial offered repeat treatment at 6 months. Profhilo's main face study followed patients to 16 weeks; any maintenance schedule beyond that is clinic practice rather than trial data.

Can you combine Profhilo or SKINVIVE with Botox or filler?

Many injectors do, often in separate sessions. The FDA notes that the safety of fillers combined with neuromodulators has not been evaluated in controlled studies, so discuss timing with your provider.

Who should not get skin boosters?

People with active skin infection or inflammation at the site, a history of severe allergies or anaphylaxis, or (for SKINVIVE) a lidocaine allergy or allergy to gram-positive bacterial proteins. Safety in pregnancy and breastfeeding has not been established.

Bottom line

In the US, the Profhilo vs SKINVIVE decision is already made for you: SKINVIVE is FDA-approved for cheek smoothness and neck lines, with controlled-trial data showing roughly 58% of people get a visible one-grade improvement in the cheeks and about 75% in neck lines at one month. Outside the US, Profhilo is a reasonable, well-tolerated alternative with very low reported complication rates, but its efficacy evidence is mostly small uncontrolled studies and one small placebo test with mixed results. Either way, expect subtle skin-quality gains, plan for maintenance, and choose an experienced, licensed injector over a particular brand. For a wider view of the category, see our skin boosters comparison, the Profhilo guide and what SKINVIVE treatment involves.

This article is for educational purposes only and is not medical advice. Talk with a board-certified dermatologist or plastic surgeon before any injectable treatment.

Sources

Meet Cera for iPhone

See your skin age, then build a routine to improve it

Turn what you learned about injectables into a personalized AM and PM routine with guided scans and product checks.

Download Cera on the App Store

Cosmetic guidance only. Cera does not diagnose medical conditions.

Get our weekly research roundup

One email a week with the latest anti-aging research, ingredient deep-dives, and treatment breakdowns. No fluff.

Free forever. Unsubscribe in one click.